ArticleScientific reports2025
IC2Bert: masked gene expression pretraining and supervised fine tuning for robust immune checkpoint blockade (ICB) response prediction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bulk RNA-seq-based prediction of immune checkpoint blockade (ICB) responses has been extensively studied to distinguish responders from non-responders. However, cohort heterogeneity remains a major challenge, hindering the robustness and generalizability of predictive models across diverse RNA-seq datasets. In this study, we present IC2Bert, a novel model that employs masked gene expression pretraining combined with domain-specific supervised fine-tuning to enhance predictive robustness across heterogeneous ICB response cohorts. To ensure an objective evaluation, we assessed the model's performance using a Leave-One-Dataset-Out Cross-Validation (LODOCV) approach. IC2Bert demonstrated significantly improved predictive accuracy and robustness compared to existing methods, effectively addressing the challenges posed by cohort heterogeneity. The IC2Bert model and its source code are publicly available on GitHub: https://github.com/data2intelligence/ic2bert .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.